PlasmaSelect AG / Miscellaneous


Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

The Board of Management of TheraSelect GmbH, a wholly owned subsidiary of
PlasmaSelect AG, informed the company’s works council today of its decision
to close the production facility at Marburg in the second quarter of the
next fiscal year.
Production of Haemaccel® for the Indian Piramal Healthcare Group will be
discontinued at that time. Bottelpack production operations in Marburg will
be transferred to a contract producer from February 2009. These measures
are aimed at avoiding the ongoing losses made by the Marburg plant.
Writeoffs generated by the measures were largely taken into consideration
in the last annual accounts. In addition, negative one-off effects from the
closure will be considered in the results of the current fiscal year.
DGAP 29.08.2008 
Language:     English
Issuer:       PlasmaSelect AG
              Pettenkoferstraße 22
              80336 München
Phone:        +49 (0)89 810 29-0
Fax:          +49 (0)89 810 29-111
ISIN:         DE0005471809
WKN:          547180
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Stuttgart, München, Hamburg, Düsseldorf
End of News                                     DGAP News-Service